Telix Pharmaceuticals (TLX) Current Deferred Revenue (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Current Deferred Revenue for 3 consecutive years, with $402000.0 the latest figure, recorded in Q4 2025.

• Quarterly Current Deferred Revenue fell 94.94% year-over-year to $402000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $402000.0 (down 94.94% YoY) and the FY2025 annual result came in at $402000.0, down 94.23% from the prior year.
• Current Deferred Revenue declined to $402000.0 in Q4 2025 per TLX's latest filing, from $7.9 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for TLX reached as high as $7.9 million in Q4 2024 and fell as low as $402000.0 in Q4 2025.
• A 3-year average of $5.4 million and a median of $7.8 million in 2023 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue grew 2.3% — and 2025, when it plunged 94.94%.
• Year by year, Current Deferred Revenue stood at $7.8 million in 2023, then rose by 2.3% to $7.9 million in 2024, then tumbled by 94.94% to $402000.0 in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $402000.0, $7.9 million, and $7.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.